Nearly 1 in 7 adults in the United States lives with chronic kidney disease, a condition that often advances quietly until ...

Getting therapeutic drugs past the blood-brain barrier has long been a major challenge in treating brain diseases. Now, researchers have explored how cholesterol-modified heteroduplex oligonucleotides ...

Officially unveiled at the American Society of Human Genetics (ASHG) 2025 meeting held in Boston, Genomics has launched Mystra, an AI-enabled human genetics platform designed to accelerate drug target ...

A version of this story appeared in Volume 103, Issue 11 Chemists and chemical biologists just keep dreaming up new ways to interfere with biomolecules. That research frequently leads to promising ...

Experts see shift toward tailored cancer therapy model Lilly awaiting details of Novo's failed trial Some drug developers target multiple biomarkers Sign up here. Globally, over 55 million people have ...

Simon Fraser University researchers are using a new approach to brain imaging that could improve how drugs are prescribed to treat Parkinson's disease. The new study, published in the journal Movement ...

Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI. The news comes as tech ...

Designing drugs is a bit like playing with Polly Pocket. The vintage toy is a plastic clam shell that contains a multi-bedroom house, a skating rink, a disco dance floor, and other fun scenarios. Kids ...

Smart multi-target drugs are reshaping modern therapeutics by addressing the complex, interconnected pathways that drive diseases like Alzheimer’s, cancer, and major depressive disorder. Advances in ...